Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) CEO Abraham Ceesay sold 2,210 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $42.11, for a total value of $93,063.10. Following the sale, the chief executive officer directly owned 537,607 shares of the company’s stock, valued at approximately $22,638,630.77. This represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Rapport Therapeutics Stock Performance
Shares of NASDAQ:RAPP opened at $42.78 on Friday. The company’s 50-day moving average is $39.28 and its 200 day moving average is $33.93. The company has a market capitalization of $2.05 billion, a P/E ratio of -16.45 and a beta of 0.94. Rapport Therapeutics, Inc. has a fifty-two week low of $13.62 and a fifty-two week high of $44.28.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.14. The company had revenue of $20.00 million for the quarter, compared to analysts’ expectations of $7.50 million. As a group, research analysts predict that Rapport Therapeutics, Inc. will post -3.26 earnings per share for the current year.
Hedge Funds Weigh In On Rapport Therapeutics
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the stock. William Blair started coverage on shares of Rapport Therapeutics in a report on Tuesday. They issued an “outperform” rating on the stock. Truist Financial began coverage on Rapport Therapeutics in a report on Monday, May 18th. They set a “buy” rating and a $56.00 price objective for the company. Raymond James Financial assumed coverage on Rapport Therapeutics in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $66.00 target price for the company. BTIG Research reaffirmed a “buy” rating and set a $65.00 price target on shares of Rapport Therapeutics in a research report on Thursday, July 16th. Finally, Leerink Partners assumed coverage on Rapport Therapeutics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.
Check Out Our Latest Analysis on RAPP
Rapport Therapeutics Company Profile
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Featured Articles
- Five stocks we like better than Rapport Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
